Last updated: September 8, 2026
Trimetrexate glucuronate is a discontinued or commercially inactive antifolate drug that was approved in the United States as Neutrexin for moderate-to-severe Pneumocystis jirovecii pneumonia in immunocompromised patients unable to tolerate trimethoprim-sulfamethoxazole. Its commercial value declined as antiretroviral therapy reduced AIDS-related opportunistic infections and newer alternatives became more practical. No meaningful current revenue base, active U.S. exclusivity, or significant biosimilar exposure is evident.
What is the FDA status of trimetrexate glucuronate?
The FDA approved trimetrexate glucuronate for treatment of moderate-to-severe Pneumocystis carinii pneumonia, now generally called Pneumocystis jirovecii pneumonia, in immunocompromised patients who could not tolerate trimethoprim-sulfamethoxazole.[1]
| Attribute |
Trimetrexate glucuronate |
| Historical brand |
Neutrexin |
| Drug class |
Lipophilic antifolate |
| Primary indication |
Moderate-to-severe Pneumocystis pneumonia |
| Route |
Intravenous |
| Treatment structure |
Administered with leucovorin rescue |
| FDA market position |
Historical approval; no significant current commercial presence |
| Primary patient population |
Immunocompromised patients, historically concentrated in AIDS care |
| Current clinical role |
Minimal to obsolete in routine U.S. practice |
The drug inhibits dihydrofolate reductase and other folate-dependent pathways. Because of antifolate toxicity, leucovorin was administered to reduce adverse effects while preserving antipneumocystis activity.[1]
The labeled treatment course was intensive and hospital-oriented. This limited use outside settings where intravenous therapy was required and standard oral or established injectable alternatives were unsuitable.
When did trimetrexate glucuronate lose exclusivity?
Trimetrexate glucuronate no longer has a commercially meaningful U.S. exclusivity position. Any original patent protection and regulatory exclusivity associated with the 1990s approval would have expired long ago.
The relevant commercial conclusion is that trimetrexate glucuronate is post-exclusivity, not a late-life branded product facing an imminent patent cliff. The product’s decline was driven primarily by market contraction and therapeutic substitution rather than by a large wave of generic entry.
Patent and Orange Book position
The FDA Orange Book is the principal source for listed patents and regulatory exclusivity associated with approved small-molecule products.[2] Trimetrexate glucuronate does not have a material current Orange Book patent position supporting branded pricing or delayed generic entry.
| IP category |
Current commercial significance |
| Active ingredient patents |
Expired or commercially irrelevant |
| Formulation patents |
No material current barrier identified |
| Method-of-use patents |
No current market exclusivity identified |
| Manufacturing patents |
Potentially relevant to process know-how, but not a visible market barrier |
| Regulatory exclusivity |
Expired |
| Orange Book listing |
No significant active protection supporting current exclusivity |
The absence of active exclusivity does not guarantee that an applicant could launch immediately. An ANDA sponsor would still need to address manufacturing controls, injectable stability, sterility, leucovorin co-administration requirements, and limited commercial demand. Those factors are business barriers rather than patent barriers.
How large was the market for trimetrexate glucuronate?
The product addressed a narrow salvage-treatment market. Its commercial opportunity depended on three conditions:
- The patient had Pneumocystis pneumonia.
- Trimethoprim-sulfamethoxazole was unsuitable because of toxicity, intolerance, or treatment failure.
- The prescriber selected an intravenous antifolate rather than another alternative.
That patient funnel was already narrow at launch. The addressable population contracted sharply after the introduction and broad adoption of combination antiretroviral therapy. Effective HIV treatment reduced the incidence of advanced immunosuppression and opportunistic infections, including Pneumocystis pneumonia.[3]
The market also suffered from the availability of established alternatives. Current clinical guidance generally places trimethoprim-sulfamethoxazole first-line for Pneumocystis pneumonia, with alternatives including atovaquone, intravenous pentamidine, and clindamycin-primaquine in selected patients.[4]
Competitive positioning against alternative treatments
| Therapy |
Typical role |
Commercial advantage over trimetrexate |
| Trimethoprim-sulfamethoxazole |
Preferred first-line treatment |
Established efficacy, broad availability, oral and IV options |
| Atovaquone |
Alternative for less severe disease or intolerance |
Oral administration and simpler outpatient use |
| Pentamidine |
Alternative for severe disease |
Established hospital use and broader historical familiarity |
| Clindamycin-primaquine |
Alternative regimen |
Non-antifolate mechanism and established guideline position |
| Trimetrexate plus leucovorin |
Historical salvage option |
Limited present-day role, IV administration, complex rescue therapy |
Trimetrexate did not have a durable differentiation advantage. Its use required physician familiarity with leucovorin rescue and monitoring for antifolate toxicity. In contrast, its competitors had larger treatment bases, clearer guideline positioning, or simpler administration.
What caused the financial decline of trimetrexate glucuronate?
The financial trajectory was structurally negative. The product moved from niche launch opportunity to declining hospital product and then to commercial obsolescence.
Phase 1: Specialty launch
At launch, trimetrexate benefited from an unmet need in AIDS-related Pneumocystis pneumonia. Patients who could not receive trimethoprim-sulfamethoxazole required alternative treatment, and intravenous hospital therapies had a defined clinical market.
Revenue potential was still constrained by the small eligible population and the product’s use as a second-line or salvage therapy.
Phase 2: Market contraction
The principal decline began as combination antiretroviral therapy improved immune recovery and reduced opportunistic infections. Pneumocystis pneumonia became less common among treated HIV patients, and prophylaxis reduced the number of advanced cases reaching hospitals.[3]
This reduced both treatment volume and the number of patients who required an unusual salvage regimen.
Phase 3: Therapeutic substitution
The remaining patients had access to established alternatives. Clinical decision-making favored therapies with broader physician familiarity, established procurement channels, and simpler administration. Trimetrexate’s intravenous delivery and leucovorin requirement increased operational burden.
Phase 4: Commercial exit
Once treatment volume fell below the threshold supporting dedicated promotion, inventory, regulatory maintenance, and commercial distribution, the product lost economic relevance. No public evidence indicates a sustained, material revenue stream in the modern pharmaceutical market.
Public company filings and product-level disclosures do not provide a dependable standalone revenue series for trimetrexate glucuronate. The product was too small and too old to support a transparent public valuation or current revenue forecast.
Does trimetrexate glucuronate face generic or Paragraph IV risk?
The practical generic risk is low in absolute commercial terms because the branded product itself has little visible market value. The legal risk from a Paragraph IV challenge is also low because the product’s original patent and exclusivity period have expired.
A potential generic sponsor would more likely pursue an ANDA based on commercial opportunism than patent litigation. The product’s small market, hospital distribution requirements, and manufacturing economics reduce the incentive for multiple entrants.
Generic launch scenarios
| Scenario |
Probability profile |
Commercial effect |
| No new entrant |
Most commercially plausible |
Market remains inactive |
| Single-source generic reintroduction |
Possible if shortage or institutional demand emerges |
Limited, episodic revenue |
| Multiple generic entrants |
Unattractive because of small volume |
Rapid price erosion |
| Branded relaunch |
Low probability |
Requires clinical or procurement change |
| Specialty supply agreement |
More plausible than broad retail launch |
Narrow institutional sales |
A Paragraph IV filing would have been more relevant during the patent-protected period. At present, the main barriers are demand, manufacturing economics, and supply-chain execution rather than patent enforcement.
What formulations and manufacturing barriers protect trimetrexate glucuronate?
The important technical issue is the injectable formulation. Trimetrexate glucuronate is not a conventional high-volume oral tablet opportunity. A commercial product must meet sterile manufacturing, potency, stability, packaging, and reconstitution requirements.
The drug’s use with leucovorin also creates a treatment-system requirement. Although leucovorin is not necessarily part of the same finished product, hospitals must coordinate both agents and maintain appropriate dosing and monitoring protocols.
Manufacturing and supply-chain considerations
A prospective manufacturer would need to address:
- Sterile drug-product production.
- Validated aseptic processing.
- Stability of the reconstituted product.
- Compatibility with diluents and infusion materials.
- Reliable active pharmaceutical ingredient supply.
- Low-volume inventory management.
- Hospital contracting and formulary access.
- Pharmacovigilance for an older product with limited current use.
These factors can prevent entry even when patent protection is absent. They do not, however, create a durable exclusivity position comparable to a patent estate.
Is there biosimilar risk for trimetrexate glucuronate?
There is no conventional biosimilar risk. Trimetrexate glucuronate is a chemically synthesized small molecule, not a biologic. A follow-on product would generally use the abbreviated new drug application pathway rather than the biosimilar pathway under section 351(k) of the Public Health Service Act.[5]
The relevant competitive threat is an ANDA generic, not a biosimilar. Because the market is small and the drug is an older injectable, a generic could face limited competition but also limited revenue.
Which companies are challenging or commercializing trimetrexate glucuronate?
No active, material patent challenge or major commercial campaign involving trimetrexate glucuronate is evident. The product’s competitive landscape is defined by therapeutic substitutes rather than by named companies pursuing a high-value patent challenge.
The companies with economic relevance are therefore manufacturers of competing Pneumocystis therapies, including suppliers of trimethoprim-sulfamethoxazole, atovaquone, pentamidine, and clindamycin-primaquine. Their products compete for the remaining treatment population, while generic manufacturers compete on procurement economics where supply is available.
Historical ownership and marketing arrangements for Neutrexin are less important to current valuation than the absence of a viable market. Any legacy licensing or distribution agreement would have limited present-day economic value unless linked to a reactivation strategy, a government supply contract, or a documented shortage.
How strong is the patent estate for trimetrexate glucuronate?
The patent estate is commercially weak. The drug has no apparent active exclusivity capable of supporting premium pricing, blocking generic entry, or generating meaningful licensing value.
| Strength factor |
Assessment |
| Composition-of-matter protection |
Expired |
| Remaining patent term |
None of material commercial value |
| Formulation protection |
No significant current barrier identified |
| Method-of-use protection |
No material current exclusivity |
| Manufacturing know-how |
Potentially useful but difficult to monetize |
| Regulatory exclusivity |
Expired |
| Litigation leverage |
Minimal |
| Licensing value |
Low without a new indication or supply contract |
A new use patent could theoretically create value, but the available evidence does not indicate an active development program or an emerging indication that would support such a strategy.
What is the revenue outlook for trimetrexate glucuronate?
The base-case revenue outlook is negligible. A reasonable commercial assessment is:
- Current branded revenue: no material public evidence.
- Current U.S. growth rate: not meaningful because the product lacks an active growth market.
- Near-term sales potential: limited to occasional institutional demand, shortages, or specialty procurement.
- Generic opportunity: narrow and price-sensitive.
- Licensing value: low.
- Development value: low unless a new indication, formulation, or public-health procurement need emerges.
The product is better classified as a dormant or historical pharmaceutical asset than as a growth-stage or patent-cliff asset.
Key Takeaways
- Trimetrexate glucuronate was approved as Neutrexin for Pneumocystis pneumonia in immunocompromised patients unable to tolerate trimethoprim-sulfamethoxazole.
- Its commercial market contracted as antiretroviral therapy reduced AIDS-related opportunistic infections.
- Trimethoprim-sulfamethoxazole, atovaquone, pentamidine, and clindamycin-primaquine displaced most practical use.
- Original patent and regulatory exclusivity are no longer commercially relevant.
- The product has no meaningful biosimilar risk because it is a small-molecule drug.
- Generic entry is legally feasible but commercially unattractive because of low demand and sterile injectable manufacturing requirements.
- Current revenue, licensing value, and litigation exposure appear negligible.
- Any future value would depend on a supply shortage, government procurement, a new indication, or a reformulated product.
FAQs
Is trimetrexate glucuronate still sold in the United States?
No material current U.S. commercial market is evident. The product is generally treated as a historical or inactive therapy rather than a routinely marketed Pneumocystis treatment.
What replaced Neutrexin for Pneumocystis pneumonia?
Current alternatives include trimethoprim-sulfamethoxazole, atovaquone, intravenous pentamidine, and clindamycin-primaquine, selected according to disease severity and patient tolerance.[4]
Can a company launch a generic trimetrexate glucuronate product?
A company could potentially pursue an ANDA if an approved reference product and applicable regulatory pathway remain available. Commercial feasibility is limited by small demand, sterile manufacturing requirements, and weak formulary pull.
Was trimetrexate glucuronate an orphan drug?
Its historical use was concentrated in a rare, serious opportunistic infection affecting immunocompromised patients. The commercial analysis should rely on the FDA’s regulatory records for any specific orphan designation or exclusivity period rather than infer current rights from the historical indication.
Does trimetrexate glucuronate have value as a licensing asset?
Its standalone licensing value is low. A transaction would require a specific commercial rationale, such as government stockpiling, a documented shortage, reactivation of a discontinued injectable, or development in a new disease setting.
References
-
U.S. Food and Drug Administration. (1993). Neutrexin (trimetrexate glucuronate) prescribing information. FDA Drugs@FDA database.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA Center for Drug Evaluation and Research.
-
Centers for Disease Control and Prevention. (1998). Guidelines for prevention of opportunistic infections among HIV-infected persons. MMWR Recommendations and Reports, 47(RR-10), 1-46.
-
National Institutes of Health, Centers for Disease Control and Prevention, and HIV Medicine Association. (2023). Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: Pneumocystis jirovecii pneumonia. ClinicalInfo.HIV.gov.
-
U.S. Food and Drug Administration. (2023). Generic drug facts and the abbreviated new drug application process. FDA.
